TL;DR
From April 2026, your GP can prescribe the weight-loss drug Mounjaro (tirzepatide) if you meet strict NHS criteria, as part of a new pay-for-performance scheme. Eligibility is currently limited to people with a very high BMI and multiple serious health conditions. Your practice may choose not to offer it, and a postcode lottery is already emerging.
The landscape for NHS weight-loss medication has fundamentally changed. This guide explains exactly what the new GP contract rules mean for accessing Mounjaro (tirzepatide) on the NHS, who qualifies, and why your local experience may vary.
What changed on 1 April 2026
The way the NHS pays GP practices to manage obesity has fundamentally shifted. From 1 April 2026, prescribing weight-loss medications like Mounjaro became part of the core GP contract in England. This was done by adding new targets to the Quality and Outcomes Framework (QOF), the system that rewards practices for meeting certain clinical standards. The change implements NICE guidance TA1026, which approved tirzepatide for NHS use. The government allocated £25 million in ring-fenced funding to support this. Crucially, this does not mean every GP can or will prescribe it immediately. The system is designed to roll out gradually to the most clinically urgent patients first, and practices must opt into the new indicators.
The new QOF indicators in plain English
The QOF is a points-based payment system. Two new indicators track obesity care. The main one relevant to Mounjaro is OB005, a pharmacotherapy indicator worth 13 QOF points. For context, a typical QOF point is worth around £200-£250 to a practice, so this indicator alone could be worth over £3,000 annually. The indicator measures whether the practice has conducted a shared-decision-making conversation about weight-management options, and where appropriate, initiated pharmacotherapy. It covers four NICE-approved drugs: orlistat, liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Mounjaro), each with its own BMI threshold. The practice must hit achievement thresholds between 50% and 80% of its eligible patients to earn the points.
Do you qualify? The Cohort 1 checklist
To be eligible for an NHS Mounjaro prescription from your GP from April 2026, you must meet ALL of the following criteria, known as Cohort 1:
- Your BMI is 40 or above. (Or 37.5 or above if you are of South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family origin, due to higher associated health risks).
- You have at least FOUR of the following FIVE long-term health conditions:
- Type 2 diabetes
- Hypertension (high blood pressure)
- Dyslipidaemia (unhealthy cholesterol/triglyceride levels)
- Established cardiovascular disease (e.g., previous heart attack or stroke)
- Obstructive sleep apnoea
- Your GP practice has opted into the new QOF obesity indicators.
The rollout timetable
If you do not meet the strict criteria above, you are not currently eligible for an NHS Mounjaro prescription from your GP. The rollout is phased.
April 2026
BMI 40+ & 4/5 comorbidities
23 June 2026
BMI 35-39.9 & 4/5 comorbidities
1 April 2027
BMI 40+ & 3/5 comorbidities
People outside these cohorts—for example, those with a BMI under 35 or with fewer comorbidities— must continue to wait. For them, the routes are a 6-24 month wait for an NHS weight-management service referral or self-funding a private prescription.
What your GP actually gets paid – the money behind the prescription
Research Spotlight
The financial incentive is direct. The government allocated £25 million in ring-fenced funding. A GP practice can earn up to around £3,000 per year through achieving the Mounjaro-related QOF indicator (OB005). An additional £1,000 is available for making referrals to weight-management programmes. This funding is intended to cover the extra staff time needed for consultations, health checks, and monitoring that accompanies prescribing. Supporters argue this funding is essential to make equitable access a reality. Critics, including some medical ethics groups, have voiced concern that it creates a potential conflict of interest, where a practice’s income is tied to prescribing a specific drug.
Why some practices will say yes and others will say no
Participation is voluntary. Some practices may decline due to workload pressures, lack of specialist nursing support, or ethical discomfort with the payment model. Others may lack the physical capacity for the required face-to-face assessments. Your local Integrated Care Board (ICB) may also issue its own guidance, leading to a documented postcode lottery.
| Reasons to Opt In | Reasons to Opt Out |
|---|---|
| Funding for extra workload | Workload and capacity pressures |
| Addressing high patient demand | Lack of specialist nursing support |
| Providing a structured pathway | Ethical concerns over payment model |
| Improving care for high-risk patients | ICB guidance advising caution |
Always ask your practice directly if they are participating before assuming you can get a prescription there.
What to ask your GP at the appointment
Key Questions for Your Consultation
If you think you might qualify, book a consultation specifically to discuss weight management. Ask:
- Is our practice participating in the new QOF obesity indicators (OB005)?
- Based on my BMI and health conditions, do I meet the current NHS eligibility criteria for Mounjaro?
- If not, what NHS-funded weight-management options are available to me now?
- If I am eligible, what does the monitoring and support programme involve?
- What is the treatment time limit on the NHS? (Note: It is currently two years).
Frequently Asked Questions
Can my GP prescribe Mounjaro from April 2026?
Yes, but only if your GP practice has opted into the new QOF scheme AND you meet the strict Cohort 1 eligibility criteria: a BMI of 40+ (or 37.5+ for certain ethnicities) and at least four of five specified serious health conditions like Type 2 diabetes or hypertension.
What is the BMI threshold for NHS Mounjaro right now?
For the first phase starting April 2026, the threshold is a BMI of 40 or above. This is lowered to 37.5 for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds. A lower threshold of BMI 35 applies to Cohort 2 from June 2026, but still requires multiple comorbidities.
Does my GP get paid extra for prescribing Mounjaro?
Yes. The practice earns money through the Quality and Outcomes Framework (QOF). The OB005 indicator is worth up to about £3,000 a year for the practice, plus up to £1,000 for referring you to a weight-management service. This funding is ring-fenced to support the extra work involved.
Can my GP prescribe Wegovy too?
No. Unlike Mounjaro, Wegovy (semaglutide for weight loss) is still only prescribable by specialist NHS weight-management services. Your GP cannot initiate a prescription for it. They can only prescribe the drugs listed in the QOF indicator: orlistat, liraglutide (Saxenda), tirzepatide (Mounjaro), and semaglutide (Wegovy) – but with Wegovy restricted to specialist initiation.
What if my practice is not signed up to the new QOF indicator?
If your practice has opted out, it cannot provide an NHS Mounjaro prescription under this new pathway. Your options are: ask for a referral to your local NHS weight-management service (be prepared for a long wait), investigate if another local practice is accepting new patients for this service, or consider self-funding a private prescription.
Verdict
The policy creates a clear, funded pathway for the highest-risk patients to access Mounjaro through their GP. However, eligibility is narrow, and the voluntary, patchwork rollout means access will be unequal. For most people hoping for a quick prescription, the reality is continued waiting. The best first step is a frank conversation with your GP to understand your local options. For other trending health news, see our articles on Megan Thee Stallion’s exhaustion and Hannah Brown’s septate uterus surgery.
